Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« More Colors and Smells | Main | Cruel to Be Kind »

March 24, 2002

What's a Project Manager to Do?

Email This Entry

Posted by Derek

One of the things that strikes experienced drug-company people is the cyclic nature of the industry. There's the boom-and-bust productivity cycle that's long characterized it, which I've had several chances to remark on. (Doubtless I'll have plenty more.)

But there are others. For example, how long should a drug discovery project take until it recommends something to the clinical development folks? A couple of years? Five years? As long as it darn well takes? Or if you think that's headed in the wrong direction, how about eighteen months? A year? Anyone for nine months? You can find companies that are trying all of these.

What happens, I think, is that a crop of managers get their experience under a given system, and while doing so they note the grievous failures all around them. Of course, there are some occasional winners, but there are always plenty more that never make it: fine projects, worthy ideas that never worked out because they just didn't have enough time (or just dragged on too long and got sidetracked, on the other hand.)

So, when they get the chance to run things, they resolve that they won't make the same mistakes. Nope, we're not having things drag on forever around here any more: you folks have a year to put it in the net, or you do something else. Or, conversely, we're not going to kill off perfectly good projects when they don't hit some arbitrary deadline: you folks keep at it until you get it right this time, OK?

This illustrates a general principle: just because you can screw things up in one direction doesn't mean you can't screw them up in another. It's a Manichean with-us-or-against-us fallacy that trips people up all the time. There's a case to be made both ways, of course, which is why this mistake has been around so long.

You really can run projects too quickly, sending half-baked slapped-together clinical candidates on to Development. And you really can let things drag on too long, pouring money and effort into a sinkhole because, hey, you've come this far already, and if you quit now you're just admitting failure, right? So the reverse approach, whichever one it is, breeds its own crop of should've-worked projects, and the managers in training resolve that they're not going to make those mistakes again. . .

Ideally, you'd split the difference, but that's the hardest way to do it. Alternately cracking the whip and witholding it can breed resentment at the perceived unequal treatment: How come those guys get to keep going when we're under pressure? How come that group got to present that junk as a candidate when they're still making us fix ours? Instead of just hearing one class of complaint, you get the whole spectrum.

Note, of course, that all the choices involve researchers complaining. It wouldn't be research, then, would it?

Comments (0) + TrackBacks (0) | Category: Drug Development


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings